


**AMENDMENTS TO THE CLAIMS:**


This listing of claims will replace all prior versions, and listings, of claims in the application:

1 (currently amended). A compound of formula I,



wherein

one of R<sup>1</sup> and R<sup>2</sup> represents a structural fragment of formula Ia



and the other represents R<sup>4</sup>;

Z represents O or N(R<sup>5</sup>);

R<sup>3</sup> represents one or more optional substituents selected from OH, halo, cyano, nitro, C(O)OR<sup>6</sup>, C<sub>1-6</sub> alkoxy or C<sub>1-6</sub> alkyl<sub>1</sub> (which two latter groups are optionally substituted and/or terminated by one or more halo or hydroxy group)<sub>1</sub> or N(R<sup>7</sup>)R<sup>8</sup>;

$R^4$  represents H, OH, halo, cyano, nitro,  $C(O)OR^6$ ,  $C_{1-6}$  alkoxy or  $C_{1-6}$  alkyl<sub>1</sub> {which two latter groups are optionally substituted and/or terminated by one or more halo or hydroxy group<sub>1</sub> or  $N(R^7)R^8$ ;

$Ar^1$  represents phenyl,  $C_{1-3}$  alkylphenyl,  $C_{1-3}$  alkylidiphenyl,  $C_{3-7}$  cycloalkyl,  $C_{1-3}$ -alkyl- $C_{3-7}$ -cycloalkyl,  $C_{1-3}$ -alkyl-di- $C_{3-7}$ -cycloalkyl, naphthyl,  $C_{1-3}$  alkylnaphthyl, thienyl, imidazolyl or isoxazolyl, all of which may be substituted by one or more substituent selected from OH, halo, cyano, nitro,  $C(O)OR^6$ ,  $C_{1-6}$  alkoxy or  $C_{1-6}$  alkyl<sub>1</sub> {which two latter groups are optionally substituted and/or terminated by one or more halo or hydroxy group<sub>1</sub> or  $N(R^7)R^8$ ;

$R^5$  represents H,  $C_{1-6}$  alkyl, phenyl or  $C_{1-3}$  alkylphenyl<sub>1</sub> {which three latter groups are optionally substituted and/or terminated by one or more substituent selected from OH, halo, cyano, nitro,  $C(O)OR^9$ ,  $C(O)N(R^{10})R^{11}$ ,  $P(O)(R^{12})R^{13}$ ,  $P(O)(OR^{14})OR^{15}$ ,  $S(O)_2(R^{16})R^{17}$ ,  $S(O)_2N(R^{18})R^{19}$ ,  $C_{1-6}$  alkoxy or  $C_{1-6}$  alkyl<sub>1</sub> {which two latter groups are optionally substituted and/or terminated by one or more halo or hydroxy group} or  $N(R^{20})R^{21}$ ;

Y represents O, S,  $S(O)$ ,  $S(O)_2$  or  $N(R^{22})$ ;

$R^{10}$  and  $R^{11}$  independently represent H,  $OR^{23}$ ,  $C(O)R^{24}$ ,  $OC(O)R^{25}$ ,  $C(O)OR^{26}$ ,  $C_{1-4}$  alkyl, {which latter group is optionally substituted and/or terminated by one or more substituent selected from  $C_{1-4}$  alkyl,  $OR^{27}$ ,  $N(R^{28})R^{29}$ ,  $C(O)OR^{30}$ ,  $C(O)N(R^{31})R^{32}$ ,  $P(O)(R^{33})R^{34}$ ,  $P(O)(OR^{35})OR^{36}$  and  $S(O)_2N(R^{37})R^{38}$ },  $-(CH_2CH_2O)_pR^{39}$  or, together with the nitrogen atom to which they are attached, form a  $C_{4-7}$  nitrogen-containing, aromatic or non-aromatic, ring which ring may contain a further heteroatom or group {as appropriate} selected from O, S and  $N(R^{40})$  and may further be substituted by one or

more substituent selected from  $C(O)R^{41}$ ,  $C(O)OR^{42}$  or  $C(O)N(R^{43})R^{44}$ ;

$R^{28}$ ,  $R^{29}$ ,  $R^{30}$ ,  $R^{31}$ ,  $R^{32}$  and  $R^{40}$  independently represent H or  $C_{1-6}$  alkyl, which latter group is optionally substituted and/or terminated by one or more substituent selected from  $C(O)R^{45}$ ,  $C(O)OR^{46}$  or  $C(O)N(R^{47})R^{48}$ ;


at each occurrence,  $R^6$ ,  $R^7$  and  $R^8$  independently represent H or  $C_{1-4}$  alkyl;

$R^9$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$ ,  $R^{17}$ ,  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$ ,  $R^{21}$ ,  $R^{22}$ ,  $R^{23}$ ,  $R^{24}$ ,  $R^{25}$ ,  $R^{26}$ ,  $R^{27}$ ,  $R^{33}$ ,  $R^{34}$ ,  $R^{35}$ ,  $R^{36}$ ,  $R^{37}$ ,  $R^{38}$ ,  $R^{39}$ ,  $R^{41}$ ,  $R^{42}$ ,  $R^{43}$ ,  $R^{44}$ ,  $R^{45}$ ,  $R^{46}$ ,  $R^{47}$  and  $R^{48}$  independently represent H or  $C_{1-4}$  alkyl;


n represents 2;

p represents 1, 2, 3, 4, 5 or 6; and


B represents a structural fragment of formula Ib, Ic, Id or Ie




Ib



Ic



Id



Ie

wherein

$X^1$  and  $X^2$  independently represent a single bond or  $CH_2$ ;

or a pharmaceutically acceptable salt thereof.

2 (original). A compound of formula I, as defined in claim 1, wherein, when B represents a structural fragment of formula Ib, Id, le or Ic in which latter fragment  $X^1$  and  $X^2$  both represent  $CH_2$ , then n represents 2.

3 (cancelled).

4 (previously presented). A compound of formula I, as defined in claim 1, wherein  $R^2$  represents a structural fragment of formula Ia and  $R^1$  represents  $R^4$ .

5 (previously presented). A compound of formula I, as defined in claim 1, wherein Z represents O or  $N(R^5)$ , in which latter case  $R^5$  represents  $C_{1-6}$  alkyl terminated by  $C(O)N(R^{10})R^{11}$ .

6 (previously presented). A compound of formula I, as defined in claim 1, wherein  $R^3$  is not present, or represents methyl, chloro or methoxy.

7 (previously presented). A compound of formula I, as defined in claim 1, wherein  $Ar^1$  represents substituted phenyl.

8 (previously presented). A compound of formula I, as defined in claim 1 wherein Y represents O.

9 (previously presented). A compound of formula I, as defined in claim 1

wherein B represents a structural fragment of formula Ib.

10 (original). A compound as claimed in Claim 1 which is:

- N-{3-[2-(4-aminoiminomethylphenyl)ethoxy]phenyl} benzenesulfonamide;  
benzenesulfonic acid- {3-[2-(4-aminoiminomethylphenyl)ethoxy]-5-methyl}phenyl ester;  
N-{3-[2-(4-aminoiminomethylphenyl)ethoxy]phenyl}-2-chlorobenzenesulfonamide;  
N-{3-[2-(4-aminoiminomethylphenyl)ethoxy]phenyl}-2-cyanobenzene-  
sulfonamide;  
N-{3-[2-(4-aminoiminomethylphenyl)ethoxy]phenyl}-2-fluorobenzene-  
sulfonamide;  
N-{3-[2-(4-aminoiminomethylphenyl)ethoxy]phenyl}-2-(trifluoromethoxy)-  
benzenesulfonamide;  
N-{3-[2-(4-aminoiminomethylphenyl)ethoxy]phenyl}-4-fluorobenzene-  
sulfonamide;  
N-{3-[2-(4-aminoiminomethylphenyl)ethoxy]phenyl}-2,5-dimethylbenzene-  
sulfonamide;  
N-{3-[2-(4-aminoiminomethylphenyl)ethoxy]phenyl}-5-chlorothiophene-2-  
sulfonamide;  
N-{3-[2-(4-aminoiminomethylphenyl)ethoxy]phenyl}-1-methylimidazole-3--  
sulfonamide;  
N-{3-[2-(4-aminoiminomethylphenyl)ethoxy]phenyl}-3,5-dimethylisoxazole-4-  
sulfonamide;  
N-{3-[2-(4-aminoiminomethylphenyl)ethoxy]phenyl} benzylsulfonamide;

N-{3-[2-(4-aminoiminomethylphenyl)ethoxy]phenyl}-2,5-dichlorothiophene-3-sulfonamide;

N-{3-[2-(4-aminoiminomethylphenyl)ethoxy]-5-methylphenyl}-2-chlorobenzenesulfonamide;

N-{3-[2-(4-aminoiminomethylphenyl)ethoxy]-2-methylphenyl}-benzenesulfonamide;

N-{5-[2-(4-aminoiminomethylphenyl)ethoxy]-2-methylphenyl}benzenesulfonamide;

N-{3-[2-(4-aminoiminomethylphenyl)ethoxy]-5-methylphenyl}benzenesulfonamide;

N-{3-[2-(4-aminoiminomethylphenyl)ethylthio]phenyl} benzenesulfonamide;

N-(2-chlorophenyl)sulfonyl-3-[2-(4-aminoiminomethylphenyl) ethoxy]-5-methylphenylaminoacetic acid, ethyl ester;

N-(2-chlorophenyl)sulfonyl-3-[2-(4-aminoiminomethylphenyl)ethoxy]-5-methylphenylaminoacetamide;

N-(2-chlorophenyl)sulfonyl-3-[2-(4-aminoiminomethylphenyl)ethoxy]-5-methylphenylaminoacetic acid;

N-(2-chlorophenyl)sulfonyl-2-{3-[2-(4-aminoiminomethylphenyl)ethoxy]-5-methylphenylamino}propanoic acid, ethyl ester;

2-{3-[2-(4-aminoiminomethylphenyl)ethoxy]-N-(2-chlorophenyl)sulfonyl-5-methylphenylamino}propanamide;

N-(2-chlorophenyl)sulfonyl-2-{3-[2-(4-aminoiminomethylphenyl)ethoxy]-5-methylphenylamino}propanoic acid;

N-(2-chlorophenyl)sulfonyl-2-{3-[2-(4-aminoiminomethylphenyl)ethoxy]-5-methylphenylamino}propanoic acid, methyl ester;

N-(2-chlorophenyl)sulfonyl-3-{3-[2-(4-aminoiminomethylphenyl)ethoxy]-5-methylphenylamino}butanoic acid, ethyl ester;

3-{3-[2-(4-aminoiminomethylphenyl)ethoxy]-N-(2-chlorophenyl)sulfonyl-5-methylphenylamino}butanamide;

N-(2-chlorophenyl)sulfonyl-3-{3-[2-(4-aminoiminomethylphenyl)ethoxy]-5-methylphenylamino}butanoic acid;

N-(2-chlorophenyl)sulfonyl-4-{3-[2-(4-aminoiminomethylphenyl)ethoxy]-5-methylphenylamino}pentanoic acid, ethyl ester;

4-{3-[2-(4-aminoiminomethylphenyl)ethoxy]-N-(2-chlorophenyl)sulfonyl-5-methylphenylamino}pentanamide;

N-(2-chlorophenyl)sulfonyl-4-{3-[2-(4-aminoiminomethylphenyl)ethoxy]-5-methylphenylamino}pentanoic acid;

N-(2-chlorophenyl)sulfonyl-5-{3-[2-(4-aminoiminomethylphenyl)ethoxy]-5-methylphenylamino}hexanoic acid, ethyl ester;

5-{3-[2-(4-aminoiminomethylphenyl)ethoxy]-N-(2-chlorophenyl)sulfonyl-5-methylphenyl amino}pentanamide;

N-(2-chlorophenyl)sulfonyl-5-{3-[2-(4-aminoiminomethylphenyl)ethoxy]-5-methylphenylamino}hexanoic acid;

N-phenylsulfonyl-3-[2-(4-aminoiminomethylphenyl)ethoxy]phenylaminoacetic acid, ethyl ester;

N-phenylsulfonyl-3-[2-(4- aminoiminomethylphenyl)ethoxy]phenylaminoacetic

acid;

N-{3-[2-(4-aminoiminomethylphenyl)ethoxy]phenyl}-N-(2-hydroxyethyl)-  
benzenesulfonamide;

N-{3-[2-(4-aminoiminomethylphenyl)ethoxy]phenyl}-N-  
(dimethyloxophosphinylmethyl)-benzenesulfonamide;

2-chlorobenzenesulfonic acid, 3-[2-(4-aminoiminomethylphenyl)ethoxy]-5-  
methylphenyl ester;

benzenesulfonic acid, 3-[2-(4-aminoiminomethylphenyl)ethoxy]phenyl ester;

2-chloro-4-fluorobenzenesulfonic acid, 3-[2-(4-aminoiminomethylphenyl)-ethoxy]-  
5-chlorophenyl ester;

2-chlorobenzenesulfonic acid, 3-[2-(4-aminoiminomethylphenyl)ethoxy]-5-  
methoxyphenyl ester;

2-chlorobenzenesulfonic acid, 3-[2-(4-aminoiminomethylphenyl)ethoxy]-5-  
ethylphenyl ester;

N-{2-[2-(4-aminoiminomethylphenyl)ethylthio]phenyl}benzenesulfonamide;

N-{2-[2-(4-aminoiminomethylphenyl)ethylthio]phenyl}-2,4,5-trichloro-  
benzenesulfonamide;

N-{2-[2-(4-aminoiminomethylphenyl)ethylthio]phenyl}-2-chloro-5-  
methoxybenzenesulfonamide;

N-{2-[2-(4-aminoiminomethylphenyl)ethylthio]phenyl}-2,5-dibromo-  
benzenesulfonamide;

N-{2-[2-(4-aminoiminomethylphenyl)ethylthio]phenyl}-2,5-dichloro-  
benzenesulfonamide;



N-{2-[2-(4-aminoiminomethylphenyl)-ethylthio]-phenyl}-2-methoxy-5-methylbenzenesulfonamide;

N-{2-[2-(4-aminoiminomethylphenyl)ethylthio]phenyl}-2,3,5,6-tetramethylbenzenesulfonamide;

N-{2-[2-(4-aminoiminomethylphenyl)ethylthio]phenyl}-3,4-dimethoxybenzenesulfonamide;

N-{2-[2-(4-aminoiminomethylphenyl)ethylthio]phenyl}-3-bromobenzenesulfonamide;

N-{2-[2-(4-aminoiminomethylphenyl)ethylthio]phenyl}-3,4-dibromobenzene-sulfonamide;

N-{2-[2-(4-aminoiminomethylphenyl)ethylthio]phenyl}-2-chloro-4-fluorobenzenesulfonamide; or

N-{2-[2-(4-aminoiminomethylphenyl)ethylthio]phenyl}-5-bromo-2-methoxybenzenesulfonamide.

11 (original). A compound of formula I, as defined in claim 1, provided that R<sup>1</sup> represents a structural fragment of formula Ia and R<sup>2</sup> represents R<sup>4</sup>.

12 (original). A compound of formula I, as defined in claim 1, provided that Ar<sup>1</sup> represents optionally substituted phenyl.

13 (original). A compound of formula I, as defined in claim 1, provided that R<sup>5</sup> is not substituted by P(O)(OR<sup>14</sup>)OR<sup>15</sup>, S(O)<sub>2</sub>(R<sup>16</sup>)R<sup>17</sup> or S(O)<sub>2</sub>N(R<sup>18</sup>)R<sup>19</sup>.

14 (original). A compound of formula I, as defined in claim 1, provided that  $R^{10}$  and/or  $R^{11}$  represent H or unsubstituted  $C_{1-4}$  alkyl.

15 (original). A compound of formula I, as defined in claim 1, provided that Y represents O, S or  $N(R^5)$ .

16 (original). A compound of formula I, as defined in claim 1, provided that B represents a structural fragment of formula Ib, Ic, or Id.

17 (original). A compound of formula I, as defined in claim 1, provided that  $R^2$  represents a structural fragment of formula Ia and  $R^1$  represents  $R^4$ .

18 (original). A compound of formula I, as defined in claim 1, provided that  $Ar^1$  does not represent optionally substituted phenyl.

19 (original). A compound of formula I, as defined in claim 1, provided that  $R^5$  is substituted by  $P(O)(OR^{14})OR^{15}$ ,  $S(O)_2(R^{16})R^{17}$  or  $S(O)_2N(R^{18})R^{19}$ .

20 (original). A compound of formula I, as defined in claim 1, provided that  $R^{10}$  and/or  $R^{11}$  do not represent H or unsubstituted  $C_{1-4}$  alkyl.

21 (original). A compound of formula I, as defined in claim 1, provided that Y

represents S(O) or S(O)<sub>2</sub>.

22 (original). A compound of formula I as defined in claim 1, provided that B represents a structural fragment of formula Ie.

23 (previously presented). A pharmaceutical formulation including a compound as defined in claim 1, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

24-34 (canceled).